553 related articles for article (PubMed ID: 12351625)
1. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
Saharinen P; Silvennoinen O
J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
[TBL] [Abstract][Full Text] [Related]
2. Jak2-Stat5 interactions analyzed in yeast.
Barahmand-Pour F; Meinke A; Groner B; Decker T
J Biol Chem; 1998 May; 273(20):12567-75. PubMed ID: 9575217
[TBL] [Abstract][Full Text] [Related]
3. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.
Ho JM; Beattie BK; Squire JA; Frank DA; Barber DL
Blood; 1999 Jun; 93(12):4354-64. PubMed ID: 10361134
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.
Saharinen P; Takaluoma K; Silvennoinen O
Mol Cell Biol; 2000 May; 20(10):3387-95. PubMed ID: 10779328
[TBL] [Abstract][Full Text] [Related]
5. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.
Saharinen P; Vihinen M; Silvennoinen O
Mol Biol Cell; 2003 Apr; 14(4):1448-59. PubMed ID: 12686600
[TBL] [Abstract][Full Text] [Related]
6. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
Fujitani Y; Hibi M; Fukada T; Takahashi-Tezuka M; Yoshida H; Yamaguchi T; Sugiyama K; Yamanaka Y; Nakajima K; Hirano T
Oncogene; 1997 Feb; 14(7):751-61. PubMed ID: 9047382
[TBL] [Abstract][Full Text] [Related]
7. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor.
Ali S; Nouhi Z; Chughtai N; Ali S
J Biol Chem; 2003 Dec; 278(52):52021-31. PubMed ID: 14522994
[TBL] [Abstract][Full Text] [Related]
8. Convergence of signaling transduced by prolactin (PRL)/cytokine chimeric receptors on PRL-responsive gene transcription.
Ferrag F; Chiarenza A; Goffin V; Kelly PA
Mol Endocrinol; 1996 Apr; 10(4):451-60. PubMed ID: 8721989
[TBL] [Abstract][Full Text] [Related]
9. A new protein containing an SH2 domain that inhibits JAK kinases.
Endo TA; Masuhara M; Yokouchi M; Suzuki R; Sakamoto H; Mitsui K; Matsumoto A; Tanimura S; Ohtsubo M; Misawa H; Miyazaki T; Leonor N; Taniguchi T; Fujita T; Kanakura Y; Komiya S; Yoshimura A
Nature; 1997 Jun; 387(6636):921-4. PubMed ID: 9202126
[TBL] [Abstract][Full Text] [Related]
10. Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-bbeta.
Rui L; Gunter DR; Herrington J; Carter-Su C
Mol Cell Biol; 2000 May; 20(9):3168-77. PubMed ID: 10757801
[TBL] [Abstract][Full Text] [Related]
11. SH2-B family members differentially regulate JAK family tyrosine kinases.
O'Brien KB; O'Shea JJ; Carter-Su C
J Biol Chem; 2002 Mar; 277(10):8673-81. PubMed ID: 11751854
[TBL] [Abstract][Full Text] [Related]
12. Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Raivola J; Hammarén HM; Virtanen AT; Bulleeraz V; Ward AC; Silvennoinen O
Front Oncol; 2018; 8():560. PubMed ID: 30560087
[TBL] [Abstract][Full Text] [Related]
13. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Liu KD; Gaffen SL; Goldsmith MA; Greene WC
Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
[TBL] [Abstract][Full Text] [Related]
14. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
15. An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells.
Nakamura N; Chin H; Miyasaka N; Miura O
J Biol Chem; 1996 Aug; 271(32):19483-8. PubMed ID: 8702638
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.
Feener EP; Rosario F; Dunn SL; Stancheva Z; Myers MG
Mol Cell Biol; 2004 Jun; 24(11):4968-78. PubMed ID: 15143188
[TBL] [Abstract][Full Text] [Related]
17. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
18. Cytokine receptor-independent, constitutively active variants of STAT5.
Berchtold S; Moriggl R; Gouilleux F; Silvennoinen O; Beisenherz C; Pfitzner E; Wissler M; Stöcklin E; Groner B
J Biol Chem; 1997 Nov; 272(48):30237-43. PubMed ID: 9374508
[TBL] [Abstract][Full Text] [Related]
19. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways.
Luo H; Rose P; Barber D; Hanratty WP; Lee S; Roberts TM; D'Andrea AD; Dearolf CR
Mol Cell Biol; 1997 Mar; 17(3):1562-71. PubMed ID: 9032284
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
